Sudan
Tuberculosis profile
| High HIV burden |
Population  2013 38 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 9.7 (6.9–13) 25 (18–34)
Mortality (HIV+TB only) 1.1 (0.94–1.4) 3 (2.5–3.6)
Prevalence  (includes HIV+TB) 73 (38–120) 192 (100–314)
Incidence  (includes HIV+TB) 41 (37–47) 108 (98–124)
Incidence (HIV+TB only) 2.6 (2.2–2.9) 6.8 (5.7–7.7)
Case detection, all forms (%) 46 (40–51)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
260 (14–720) 340 (2–680)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 5 980   588
Pulmonary, clinically diagnosed 7 586    
Extrapulmonary 4 902    
       
Total new and relapse 19 056    
Previously treated, excluding relapses 1 125    
Total cases notified 20 181    
Among 20 181 new cases:
2 181 (11%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 35 (<1%) 79 (5%) 171
Laboratory-confirmed RR-/MDR-TB cases     95
Patients started on MDR-TB treatment     72
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 367 (27)
HIV-positive TB patients 325 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 127 (39)
HIV-positive people screened for TB 4 456  
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 75
Previously treated cases registered in 2012 64
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 53
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0.1
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 14
% Funded domestically 31%
% Funded internationally 67%
% Unfunded 2%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-04 Data: www.who.int/tb/data